Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
PRMEthis companyPrime Medicine, Inc.	$4.37	-2.57×	4.27×	111.44×	-2.91×	-102.2%	-58.1%	-4498.1%	-4342.4%	-166.4%	-66.5%	-32.4%	0.96×	-0.27×	0×	4.84×	0.0%	2	-5.36	1	D+
BEAMBeam Therapeutics Inc.	$27.00	-34.22×	2.21×	19.62×	-196.25×	-229.8%	84.0%	-274.6%	-57.2%	-6.5%	-27.4%	-13.1%	0.24×	0.08×	-8.77×	13.09×	0.0%	2	4.01	1	C-
CRBUCaribou Biosciences, Inc.	$0.46	-1×	1.22×	13.31×	-1.13×	-908.6%	67.3%	-1220.5%	-1327.4%	-121.2%	-89.8%	-75.7%	0.22×	-0.1×	0×	5.71×	0.0%	3	-7.25	2	C
DSGNDesign Therapeutics, Inc.	$10.55	-7.69×	2.53×	0×	-7.55×	-97.5%	0.0%	0.0%	0.0%	-32.8%	-37.1%	-10.1%	0.01×	0.22×	0×	17.14×	0.0%	1	26.54	2	C
EDITEditas Medicine, Inc.	$2.68	-1.14×	6.67×	4.49×	-0.75×	-308.6%	100.0%	-245.2%	-395.0%	-586.6%	-65.6%	-91.2%	2.81×	0.47×	-16.1×	3.54×	0.0%	3	-8.13	2	C
MGXMetagenomi, Inc. Common Stock	$0.73	-0.69×	0.38×	2.39×	-0.72×	-11909.0%	78.9%	-380.9%	-348.5%	-55.4%	-47.0%	-148.3%	0.26×	0.01×	0×	7.22×	0.0%	2	-3.67	2	C
Peer median	—	-1.14×	2.21×	4.49×	-1.13×	-308.6%	78.9%	-274.6%	-348.5%	-55.4%	-47.0%	-75.7%	0.24×	0.08×	0×	7.22×	0.0%	2	-3.67	2	—